Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
April 22 2024 - 4:15PM
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the
“Company”), a commercial-stage medical device company that develops
and markets customizable, incision-free therapies for the ablation
of diseased tissue, will announce its first quarter 2024 financial
results after market close on Thursday, May 9, 2024.
Profound management will host a conference call
at 4:30 p.m. ET to review the financial results and discuss
business developments in the period.
First Quarter 2024 Results Conference
Call Details:
Date: |
Thursday, May 9, 2024 |
Time: |
4:30 p.m. ET |
Live Call Registration:
https://register.vevent.com/register/BI477e53fa85fe419682e13b58f27341b0
The call will also be broadcast live and
archived on the Company's website at www.profoundmedical.com under
"Webcasts" in the Investors section.
About Profound Medical
Corp.
Profound is a commercial-stage medical device
company that develops and markets customizable, incision-free
therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a
technology that combines real-time MRI, robotically-driven
transurethral ultrasound and closed-loop temperature feedback
control. TULSA-PRO® is designed to provide customizable and
predictable radiation-free ablation of a surgeon-defined prostate
volume while actively protecting the urethra and rectum to help
preserve the patient’s natural functional abilities.
TULSA-PRO® has the potential to be a flexible technology in
customizable prostate ablation, including intermediate stage
cancer, localized radio-recurrent cancer, retention and hematuria
palliation in locally advanced prostate cancer, and the transition
zone in large volume benign prostatic hyperplasia (“BPH”).
TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared
by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an
innovative therapeutic platform that is CE marked for the treatment
of uterine fibroids and palliative pain treatment of bone
metastases. Sonalleve® has also been approved by the China
National Medical Products Administration for the non-invasive
treatment of uterine fibroids and has FDA approval under a
Humanitarian Device Exemption for the treatment of osteoid osteoma.
The Company is in the early stages of exploring additional
potential treatment markets for Sonalleve® where the
technology has been shown to have clinical application, such as
non-invasive ablation of abdominal cancers and hyperthermia for
cancer therapy.
For further information, please
contact:
Stephen KilmerInvestor
Relationsskilmer@profoundmedical.com T: 647.872.4849
Profound Medical (TSX:PRN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Profound Medical (TSX:PRN)
Historical Stock Chart
From Aug 2023 to Aug 2024